RSV F protein vaccine reduces rates of maternal and infant RSV
1. In this randomized controlled trial, there was a decreased risk of any and severe respiratory syncytial virus (RSV) lower ...
Tag: pulmonology
Discharge rates in American emergency departments unchanged for pulmonary embolism
1. In this serial cross-sectional analysis, discharge rates for acute pulmonary embolism (PE) in emergency departments (EDs) in the United ...
Ibuprofen does not improve bronchopulmonary dysplasia outcomes
1. This randomized controlled trial showed no evidence that ibuprofen treatment for bronchopulmonary dysplasia reduced premature infant mortality. 2. This ...
Simnotrelvir to reduces the symptoms of mild to moderate COVID-19
1. In this randomized controlled trial, patients experiencing symptomatic coronavirus disease 2019 (COVID-19) saw significant improvement in symptom resolution times ...
mRNA-based vaccine efficacious in preventing symptomatic RSV infection
1. In this randomized-controlled trial, an mRNA-based vaccine was efficacious at preventing symptomatic infection with respiratory syncytial virus (RSV) involving ...
Amikacin prevents ventilator-associated pneumonia in mechanically ventilated patients
1. In this randomized controlled trial, rates of ventilator-associated pneumonia (VAP) were lower in ventilated patients using amikacin as compared ...
Amikacin prevents ventilator-associated pneumonia in mechanically ventilated patients
1. In this randomized controlled trial, ventilator-associated pneumonia (VAP) was prevented by employing inhaled amikacin in mechanically ventilated patients exceeding ...
Fluticasone furoate does not improve outpatient COVID-19 outcomes
1. In this randomized controlled trial, inhaled fluticasone furoate did not shorten the time to recovery for non-hospitalized patients with ...
#VisualAbstract: Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...
Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...